Introduction: Acute lymphoblastic leukemia is a type of leukemia, which is most
current in children. ALL involves lymphocyte cells and contains about 30% of childhood
cancers. thiosemicarbazones complexes are range of chemical compounds that have antitumor
activity. Their antitumor activity is related to inhibition of ribonucleotide reductase (RNR),
reactive oxygen production, inhibition of topoisomerase II, mitochondrial dysfunction and
inhibition of multiple drug resistance protein (MDR1). The purpose of this study was to
evaluate the effect of thiosemicarbazones complexes with Ni metal ions on expression changes
of LncRNA CASC15 in the acute lymphoblastic leukemia Jurkat E6.1 cell line.
Methods: In this study, different concentrations of thiosemicarbazones
complexes (Ni) were examined with the MTT test. Then thiosemicarbazones complexes (Ni)
were prepared at 51 and 61µM concentrations. The Jurkat E6.1 cell line (Acute lymphoblastic
leukemia) was treated by Ni at 48 hours after cell passage. Then RNA extraction and cDNA
synthesis were performed and the expression changes of LncRNA CASC15 and GAPDH as
the Housekeeping gene were evaluated by Real Time PCR. Finally, the results of Real Time
PCR were analyzed by Rest 2002 Software.
Results: The Results of the research showed that the expression of LncRNA CASC15
significantly decreased after treatment with thiosemicarbazones complexes (Ni) at 51 and
61µM concentrations in 48 hours compared with non-thiosemicarbazones complexes (Ni)
samples (as a control groups, p-value < 0.001). Conforming to the results, it has been found
that concentrations of 51 and 61µM Ni in 48 hours are the optimal concentrations and time of
the effect of this drug. The expression of LncRNA CASC15 at the indicated concentrations and
time were 0.714 and 0.992.
Conclusion: According to the results of the study of expression changes in
LncRNA CASC15 under thiosemicarbazones complexes (Ni) treatment, it can be concluded
that both concentrations of the drug were effective in reducing the expression of LncRNA
CASC15. The results showed at the concentration of 51µM of Ni drug, a further decrease in
expression of LncRNA CASC15 was observed, which is the most effective concentration of
the drug. Overall, thiosemicarbazones complexes (Ni) had a positive effect on the LncRNA
CASC15 oncogene reduction process over a period of 48 hours and at the studied
concentrations, this decrease in expressions was statistically significant (p-value < 0.001).
Evidence suggests that the thiosemicarbazones complexes (Ni) has high potential for cancer
control and treatment.